Search

Your search keyword '"Novartis Pharmaceuticals Corp. -- Intellectual property"' showing total 23 results
Start Over Descriptor "Novartis Pharmaceuticals Corp. -- Intellectual property"
23 results on '"Novartis Pharmaceuticals Corp. -- Intellectual property"'

3. Patent Issued for LFA-1 Inhibitor And Methods Of Preparation And Polymorph (USPTO 10,906,892)

Subjects
Novartis Pharmaceuticals Corp. -- Intellectual property, Intellectual property, Methods, Pharmaceutical industry -- Intellectual property -- Methods
Abstract

2021 FEB 19 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Patent Business Week -- A patent by the inventors Zeller, James Robert (Scottsdale, AZ); Venkatraman, Sripathy (Slingerlands, [...]

Published
2021

4. Federal Circuit Affirms District Court Decision Upholding Validity of Novartis's Afinitor(r) Patent Covering Method of Treating Advanced Renal Cell Carcinoma

Subjects
Venable L.L.P. -- Intellectual property, Novartis AG -- Intellectual property, Novartis Pharmaceuticals Corp. -- Intellectual property, Law firms -- Intellectual property -- Methods, Pharmaceutical industry -- Intellectual property -- Methods, Cancer treatment -- Methods, Renal cell carcinoma -- Methods, Generic drugs -- Methods, Antineoplastic agents -- Methods, Sorafenib, Sunitinib, Everolimus, Cancer, Carcinoma, General interest, News, opinion and commentary, Afinitor (Medication)
Abstract

Washington: Venable LLP has issued the following press release: On May 13, 2019, the Court of Appeals for the Federal Circuit ruled in favor of Venable Fitzpatrick's clients Novartis Pharmaceuticals [...]

Published
2019

5. The Scope of Waivers of Privilege in Patent Infringement Matters

Subjects
Novartis Pharmaceuticals Corp. -- Intellectual property, Sharper Image Corp. -- Intellectual property, Consumer electronics industry -- Intellectual property, Pharmaceutical industry -- Intellectual property, Patent infringement, Consumer electronics industry, Business, regional, Law
Published
2005

6. The Scope of Waivers of Privilege in Patent Infringement Matters

Subjects
Novartis Pharmaceuticals Corp. -- Intellectual property, Sharper Image Corp. -- Intellectual property, Consumer electronics industry -- Intellectual property, Pharmaceutical industry -- Intellectual property, Patent infringement, Consumer electronics industry, Business, regional, Law
Published
2005

7. BRIEF: Mylan faces patent challenge on menopause drug

Subjects
United States. Food and Drug Administration, Novartis Pharmaceuticals Corp. -- Intellectual property, Mylan L.L.C. -- Intellectual property, Noven Pharmaceuticals Inc. -- Intellectual property, Generic drugs -- Intellectual property, Menopause, Patents, Pharmaceutical industry -- Intellectual property, Patent/copyright issue, General interest, News, opinion and commentary, Vivelle (Medication) -- Intellectual property
Abstract

March 02--Mylan Inc. of Canonsburg said it's been sued in U.S. District Court in New York by Vivelle Ventures LLC, Noven Pharmaceuticals Inc. and Novartis Pharmaceuticals Corp., in connection with [...]

Published
2011

8. Noven Confirms Filing of Abbreviated New Drug Application for Generic Version of Exelon[R] (Rivastigmine Transdermal System)

Subjects
United States. Food and Drug Administration, Novartis Pharmaceuticals Corp. -- Intellectual property, Hisamitsu Pharmaceutical Company Inc. -- Intellectual property, Exelon Corp. -- Intellectual property, Noven Pharmaceuticals Inc. -- Intellectual property, Electric utilities -- Intellectual property, Generic drugs, Transdermal medication, Rivastigmine, Pharmaceutical industry -- Intellectual property, Business, Business, international, Drug Price Competition and Patent Term Restoration Act of 1984
Abstract

Paragraph IV Litigation Initiated by Patent Holders MIAMI & NEW YORK -- Noven Pharmaceuticals, Inc. today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. [...]

Published
2013

9. Mylan announces settlement agreement for its first-to-file generic version of Vivelle-Dot

Subjects
Novartis Pharmaceuticals Corp. -- Intellectual property, Mylan Inc. -- Intellectual property, Generic drugs, Pharmaceutical industry -- Intellectual property, Business, Chemicals, plastics and rubber industries, Vivelle (Medication)
Abstract

Mylan Inc has settled a patent litigation lawsuit with Novartis Pharmaceuticals Corp related to Vivelle-Dot (Estradiol Transdermal System USP, Twice-Weekly, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day and 0.075 mg/day and [...]

Published
2011

10. Intellipharmaceutics Provides Additional Update on Activities Related to 30mg Generic Version of Focalin XR(R)

Subjects
Novartis Pharmaceuticals Corp. -- Intellectual property, Novartis Pharma AG -- Intellectual property, Celgene Corp. -- Intellectual property, Generic drugs, Pharmaceutical industry -- Intellectual property, Banking, finance and accounting industries, Business, Focalin (Medication)
Abstract

Byline: Staff TORONTO, Apr 5, 2011 (GlobeNewswire via COMTEX) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) today announced the following with regard to its generic drug commercialization activities. Further to its [...]

Published
2011

11. Mylan confirms first-to-file patent challenge relating to Vivelle-Dot

Subjects
United States. Food and Drug Administration, Novartis Pharmaceuticals Corp. -- Intellectual property, Mylan L.L.C. -- Intellectual property, Noven Pharmaceuticals Inc. -- Intellectual property, Generic drugs -- Intellectual property, Patents, Pharmaceutical industry -- Intellectual property, Patent/copyright issue, Business, Chemicals, plastics and rubber industries, Vivelle (Medication) -- Intellectual property
Abstract

Mylan Inc confirmed that the company has been sued by Vivelle Ventures LLC, Noven Pharmaceuticals Inc and Novartis Pharmaceuticals Corp in connection with the filing of an Abbreviated New Drug [...]

Published
2011

12. Mylan Confirms First-to-File Patent Challenge Relating to Vivelle-Dot

Subjects
United States. Food and Drug Administration, Novartis Pharmaceuticals Corp. -- Intellectual property, Noven Pharmaceuticals Inc. -- Intellectual property, Generic drugs, Patents, Pharmaceutical industry -- Intellectual property, Patent/copyright issue, Business, News, opinion and commentary, Vivelle (Medication)
Abstract

Expects to qualify for 180 days of marketing exclusivity for all strengths PITTSBURGH, March 1, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company has been sued [...]

Published
2011

13. Watson launches generic Exelon

Subjects
Novartis Pharmaceuticals Corp. -- Intellectual property, Novartis Pharma AG -- Intellectual property, Exelon Corp. -- Intellectual property, Watson Pharmaceuticals Inc. -- Intellectual property, Electric utilities -- Intellectual property, Generic drugs, Pharmaceutical industry -- Intellectual property, Business, Chemicals, plastics and rubber industries
Abstract

Watson Pharmaceuticals Inc (Watson) announced that, under a settlement with Novartis Pharmaceuticals Corp, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd, and Proterra AG (collectively 'Novartis'), Watson has commenced [...]

Published
2010

14. Intellipharmaceutics announces approval of settlement related to ADHD Drug Focalin XR

Subjects
Novartis Pharmaceuticals Corp. -- Intellectual property, Novartis Pharma AG -- Intellectual property, Par Pharmaceutical Inc. -- Intellectual property, Celgene Corp. -- Intellectual property, Generic drugs, Drug approval, Attention-deficit hyperactivity disorder, Pharmaceutical industry -- Intellectual property, Business, Chemicals, plastics and rubber industries, Focalin (Medication)
Abstract

Intellipharmaceutics International Inc (Intellipharmaceutics) and its wholly owned subsidiary Intellipharmaceutics Corp announced that it and its licensee and development partner Par Pharmaceutical Inc (Par) have received confirmation that the patent [...]

Published
2010

15. Intellipharmaceutics Announces Approval of Settlement Related to ADHD Drug Focalin XR(R)

Subjects
Novartis Pharmaceuticals Corp. -- Intellectual property, Novartis Pharma AG -- Intellectual property, Elan Corporation PLC -- Intellectual property, Par Pharmaceutical Inc. -- Intellectual property, Celgene Corp. -- Intellectual property, Generic drugs, Drug approval, Attention-deficit hyperactivity disorder, Pharmaceutical industry -- Intellectual property, Banking, finance and accounting industries, Business, Focalin (Medication)
Abstract

Byline: Staff TORONTO, May 6, 2010 (GlobeNewswire via COMTEX) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) and its wholly owned subsidiary Intellipharmaceutics Corp. (collectively 'Intellipharmaceutics' or the 'Company') today announced that [...]

Published
2010

16. Patent Issued for Compounds Containing S-N-Valeryl-N-{[2'-(1H-Tetrazole-5-Yl)-Biphenyl-4-Yl]-Methyl}-Valine and (2R,4S)-5-Biphenyl-4-Yl-4-(3-Carboxy-Propionylamino)-2-Methyl-Pentanoic Acid Ethyl Ester

Subjects
Novartis Pharmaceuticals Corp. -- Intellectual property, Intellectual property, Patent/copyright issue, Biphenyl (Compound), Patents, Amino acids, Pharmaceutical industry -- Intellectual property
Abstract

By a News Reporter-Staff News Editor at Pharma Business Week -- Novartis Pharmaceuticals Corporation (East Hanover, NJ) has been issued patent number 8877938, according to news reporting originating out of [...]

Published
2014

17. Drug maker settles patent dispute

Subjects
Watson Pharmaceuticals Inc. -- Intellectual property, Novartis Pharmaceuticals Corp. -- Intellectual property, Exelon Corp. -- Intellectual property, Pharmaceutical industry -- Intellectual property, Patents, Patent/copyright issue, Business, Business, regional, General interest
Published
2007

18. Patent Issued for Solid Dosage Forms of Valsartan, Amlodipine and Hydrochlorothiazide and Method of Making the Same

Subjects
Novartis Pharmaceuticals Corp. -- Intellectual property, Intellectual property, Methods, Patent/copyright issue, Diuretics -- Methods, Patents -- Methods, Amlodipine -- Methods, Pharmaceutical industry -- Intellectual property -- Methods
Abstract

By a News Reporter-Staff News Editor at Diabetes Week -- Novartis Pharmaceuticals Corporation (East Hanover, NJ) has been issued patent number 8435563, according to news reporting originating out of Alexandria, [...]

Published
2013

19. Noven Confirms Filing of Abbreviated New Drug Application for Generic Version of Exelon[R] Rivastigmine Transdermal System

Subjects
Novartis Pharmaceuticals Corp. -- Intellectual property, Hisamitsu Pharmaceutical Company Inc. -- Intellectual property, Exelon Corp. -- Intellectual property, United States. Food and Drug Administration, Intellectual property, Transdermal drug delivery systems, Generic drugs, Rivastigmine, Electric utilities -- Intellectual property, Pharmaceutical industry -- Intellectual property, Transdermal medication, Drug Price Competition and Patent Term Restoration Act of 1984
Abstract

By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Noven Pharmaceuticals, Inc. confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food [...]

Published
2013

20. Eon announces trial cancellation. (Digest)

Subjects
Novartis Pharmaceuticals Corp. -- Intellectual property, Eon Labs Inc. -- Intellectual property, Intellectual property, Pharmaceutical industry -- Intellectual property
Abstract

A trial in which Novartis Pharmaceuticals Corp. brought a patent infringement case against Eon Labs Inc. has been canceled. Eon's counsel says it has been advised that the court intends [...]

Published
2002

21. Mylan Confirms First-to-File Patent Challenge Relating to Vivelle-Dot[R]

Subjects
United States. Food and Drug Administration, Novartis Pharmaceuticals Corp. -- Intellectual property, Noven Pharmaceuticals Inc. -- Intellectual property, Generic drugs, Patents, Pharmaceutical industry -- Intellectual property, Patent/copyright issue, Advertising, marketing and public relations, Vivelle (Medication)
Abstract

Mylan Inc. (Nasdaq: MYL) confirmed that the company has been sued by Vivelle Ventures LLC, Noven Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation in connection with the filing of an Abbreviated [...]

Published
2011

22. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt iloperidone in the U.S

Subjects
Novartis Pharmaceuticals Corp. -- Intellectual property, Fanapt (Medication) -- Intellectual property, Intellectual property, Patent/copyright issue, Drugs -- Intellectual property, Antipsychotic agents, Patents, Pharmaceutical industry -- Intellectual property, Antipsychotic drugs
Abstract

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its [...]

Published
2010

23. Barr confirms patent challenge to Novartis Ritalin

Subjects
Novartis Pharmaceuticals Corp. -- Intellectual property, Barr Laboratories Inc. -- Intellectual property, Patents, Pharmaceutical industry -- Intellectual property, Patent/copyright issue, Pharmaceuticals and cosmetics industries
Abstract

US generics firm Barr Laboratories says it has initiated a challenge of the patents listed by Novartis Pharmaceuticals in connection with its Ritalin LA (methylphenidate hydrochloride) extended-release capsules, 10mg, 20mg, [...]

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results